Abstract:Mounting evidence suggests a prominent role for alpha-synuclein (a-syn) in neuronal cell function. Alterations in the levels of cellular a-syn have been hypothesized to play a critical role in the development of Parkinson's disease (PD); however, mechanisms that control expression of the gene for a-syn ( SNCA ) in cis and trans as well as turnover of a-syn are not well understood. We analyzed whether methyl-CpG binding protein 2 (MeCP2), a protein that specifically binds methylated DNA, thus regulating transcription, binds at predicted binding sites in intron 1 of the SNCA gene and regulates a-syn protein expression Chromatin immunoprecipitation (ChIP) and electrophoretic mobility-shift assays (EMSA) were used to confirm binding of MeCP2 to regulatory regions of SNCA . Site-specific methylation and introduction of localized mutations by CRISPR/Cas9 were used to investigate the binding properties of MeCP2 in human SK-N-SH neuroblastoma cells. The significance of MeCP2 for SNCA regulation was further investigated by overexpressing MeCP2 and mutated variants of MeCP2 in MeCP2 knockout cells. We found that methylation-dependent binding of MeCP2 at a restricted region of intron 1 of SNCA had a significant impact on the production of a-syn. A single nucleotide substitution near to CpG1 strongly increased the binding of MeCP2 to intron 1 of SNCA and decreased a-syn protein expression by 60%. In contrast, deletion of a single nucleotide closed to CpG2 led to reduced binding of MeCP2 and significantly increased a-syn levels. In accordance, knockout of MeCP2 in SK-N-SH cells resulted in a significant increase in a-syn production, demonstrating that SNCA is a genomic target for MeCP2 regulation. In addition, the expression of two mutated MeCP2 variants found in Rett syndrome (RTT) showed a loss of their ability to reduce a-syn expression. This study demonstrates that methylation of CpGs and binding of MeCP2 to intron 1 of the SNCA gene plays an important role in the control of a-syn expression. In addition, the changes in SNCA regulation found by expression of MeCP2 variants carrying mutations found in RTT patients may be of importance for the elucidation of a new molecular pathway in RTT, a rare neurological disorder caused by mutations in MECP2 .

Increased binding of MeCP2 to the GAD1 and RELN promoters may be mediated by an enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum

Locus-specific DNA methylation of Mecp2 promoter leads to autism-like phenotypes in mice

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Genome-wide DNA methylation profiles of autism spectrum disorder

5-Hydroxymethylcytosine Alterations in the Human Postmortem Brains of Autism Spectrum Disorder

Complex epigenetic regulation of engrailed-2 (EN-2) homeobox gene in the autism cerebellum

Identification of Autism-Related MECP2 Mutations by Whole-Exome Sequencing and Functional Validation

MeCP2 and neurodevelopmental disorders

Gender differences in methylation and hydroxymethylation levels of MECP2

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus

MeCP2: Multifaceted Roles in Gene Regulation and Neural Development

The Alpha-Synuclein Gene (SNCA) is a Genomic Target of Methyl-CpG Binding Protein 2 (MeCP2)—Implications for Parkinson's Disease and Rett Syndrome

Epigenetic dysregulation of SHANK3 in brain tissues from individuals with autism spectrum disorders.

Gut microbiome and metabolic profiles of mouse model for MeCP2 duplication syndrome

The Loss of Methyl-Cpg Binding Protein 1 Leads to Autism-Like Behavioral Deficits

MeCP2 links heterochromatin condensates and neurodevelopmental disease

[Mutational analysis of the methyl-CpG-binding protein 2 (MECP2) gene in male autism patients].

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

Hypermethylation of the enolase gene ( ENO2 ) in autism

A multi-model approach defines function altering MECP2 missense variants identified in individuals with autism spectrum disorder

Critical Regulation Of A Ndime/Mef2c Axis In Embryonic Stem Cell Neural Differentiation And Autism